Researchers from the laboratory SABNP and the start-up Synsight, both Genopole entities supported by GIP teams, have developed a new, integrated drug screening approach built upon computational modeling, the structural analysis of biological molecules and a patented technology for the study of RNA-protein interactions within living cells. The team aims to enable the exploration of the modulation or inhibition of these interactions for therapeutic purposes, a pathway heretofore hampered by a lack of methodologies, but one holding great promise in certain cancers and other pathologies. Indeed, in living systems, bindings between proteins and RNA (e.g., protein-coding messenger RNA, other non-coding RNA with diverse biological roles) are essential phenomena for cell function, and thus essential for the entire organism.